Management of migraine in Australian general practice

@article{Stark2007ManagementOM,
  title={Management of migraine in Australian general practice},
  author={Richard James Stark and Lisa Valenti and Graeme C Miller},
  journal={Medical Journal of Australia},
  year={2007},
  volume={187}
}
Objectives: To determine the proportion of patients who have a diagnosis of migraine in a sample of Australian general practice patients, and to review the prophylactic and acute drug treatments used by these patients. 

Erenumab in Chronic Migraine: An Australian Experience

To determine the effectiveness and safety of erenumab in patients with chronic migraine in the real‐world setting of 3 headache centers in Australia, three clinical trials are conducted.

Treatment of migraine and tension-type headache in Croatia

The treatment of primary headaches in Croatia should be improved, as the majority of patients are only partially satisfied with their current treatment, and almost one-third are not satisfied.

Prevalence of Migraine in the Elderly: A Narrated Review

Difficulty in the differentiation of migraine from vascular insults such as transient ischemic attacks and amyloid angiopathy and other multiple comorbidities, polypharmacy and age-related changes in pharmacodynamics and pharmacokinetics makes treatments for this cohort challenging but necessary.

Chinese herbal medicine for migraine management: A hospital-based retrospective analysis of electronic medical records

Chinese herbal medicine (CHM) can be used as an alternative to conventional pharmacotherapies for migraine and is worth further evaluation in randomized controlled trials.

Managing migraine with over-the-counter provision of triptans: the perspectives and readiness of Western Australian community pharmacists

Pharmacists were knowledgeable regarding triptans and recognised symptoms requiring referral; migraine knowledge could be improved; professional pharmacy bodies should consider these findings when recommending drugs suitable for down-scheduling for pharmacist recommendation.

Real-world effectiveness of onabotulinumtoxinA treatment for the prevention of headaches in adults with chronic migraine in Australia: a retrospective study

This study provides additional clinical evidence for the consistent effectiveness of onabotulinumtoxinA for the treatment of CM in Australia, made evident by reductions in migraine days, severe headache days, and HIT-6 scores from baseline.

Emergency department treatment of primary headaches in children and adolescents

While little evidence exists, most authors agree with an initial trial of ibuprofen followed by sumatriptan nasal spray for children over 12 years of age for those with persistent symptoms, including those without a previous diagnosis.

Prevalence and factors associated with the use of primary headache diagnostic criteria by chiropractors

Clinical management factors associated with chiropractors who report the use of primary headache diagnostic criteria are examined to influence practitioner clinical decision-making around headache patient management including their co-management with other health care providers.

Migraine prophylaxis

The approach to menstrual migraine and migraine with prominent aura may differ from that for typical migraine, and novel approaches are being explored for these problems.

A critical review of manual therapy use for headache disorders: prevalence, profiles, motivations, communication and self-reported effectiveness

There is a need for more rigorous public health and health services research in order to assess the role, safety, utilization and financial costs associated with manual therapy treatment for headache.

References

SHOWING 1-10 OF 24 REFERENCES

Migraine Diagnosis and Treatment: Results From the American Migraine Study II

Objective.—A population‐based survey was conducted in 1999 to describe the patterns of migraine diagnosis and medication use in a representative sample of the US population and to compare results

Migraine--current understanding and treatment.

The epidemiology, pathophysiology, and preventive and symptomatic treatment of migraine is described, with special attention to drug therapy with the triptans.

Prevalence and Burden of Migraine in the United States: Data From the American Migraine Study II

The prevalence, sociodemographic profile, and the burden of migraine in the United States in 1999 and to compare results with the original American Migraine Study, a 1989 population‐based study employing identical methods are described.

Prevalence and Diagnosis of Migraine in Patients Consulting Their Physician With a Complaint of Headache: Data From the Landmark Study

To improve the recognition of migraine, patients with a stable pattern of episodic, disabling headache and a normal physical exam should be considered to have migraine in the absence of contradictory evidence.

Practice parameter: Evidence-based guidelines for migraine headache (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology

In the article “Practice parameter: Evidence-based guidelines for migraine headache (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy …

Medication-overuse headache: a worldwide problem

General practice activity in Australia 2002-03

number Subject Number of respondents Number of GPs 95 Cultural background of patients attending general practice 6,035 202 96 Inhaled corticosteroid use for asthma management 5,911 201 97 Statin

Topiramate 100 mg/day in migraine prevention: a pooled analysis of double‐blind randomised controlled trials

Topiramate was superior to placebo as measured by the reduction in mean monthly migraine frequency, monthly migraine days and monthly migraine duration and the therapeutic effect was consistent throughout the different studies and independent of gender.

How representative are patients in general practice morbidity surveys?

It is suggested that sampling of patients from randomly selected general practitioners can produce useful representative samples for studies of morbidity even when doctor participation rates are as low as 29%.